Mergers and acquisitions (M&A) are always exciting news. But the temperature has really been dialed up on the upcoming mega-merger between two big Canadian cannabis players, Aphria (NASDAQ: APHA) and Tilray (NASDAQ: TLRY) . Since marijuana sales have skyrocketed amid the pandemic, the sector is the talk of the town. The expectation surrounding the new entity captured investors' attention even more, elevating the stock prices of both Aphria and Tilray this year. So far in 2021, Tilray's stock has gained 227%, while Aphria has surged 180%. The industry benchmark, the Horizons Marijuana Life Sciences ETF , has gained 63% over the same time frame.
Investors sure did enjoy solid gains from the recent surge, and are expecting even more upside. In my opinion, selling Aphria or Tilray's shares to enjoy short-term returns is not the best option right now. Here's why, if you have the time to wait, holding on for the long haul is the wiser move.
Image source: Getty Images.
For further details see:
The Worst Mistake Aphria Stock Investors Can Make Right Now